Mehdi Mohamadnejad1, Mandana Ashrafi1, Kamran Alimoghaddam2, Masoud Vosough3, Soura Mardpour4, Vajiheh Azimian4, Nasser Aghdami4, Mohammad Bagheri1, Leila Abdollahzadeh1, Maryam Bashtar2, Shahram Akhlaghpoor5, Ardeshir Ghavamzadeh2, Hossein Baharvand3, Reza Malekzadeh1. 1. Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2. Hematology, Oncology, BMT Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran ; Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. 4. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. 5. Noor Medical Imaging Center, Tehran, Iran.
Abstract
BACKGROUND: During the resent years there has been interest in using bone marrow stem cells to treat liver cirrhosis. However, there is a potential concern for malignant transformation after stem cell therapy. The aim of this study was to evaluate the development of hepatocellular carcinoma (HCC) after autologous bone marrow stem cell transplantation for liver cirrhosis. METHODS: All the patients who underwent autologous stem cell transplantation for liver cirrhosis between 2005 and 2011 at our center were enrolled. Cellular infusion was made through peripheral vein, portal vein, or hepatic artery.The patients were invited to undergo screening for hepatocellular carcinoma. The screening was made with ultrasonography and alpha-feto protein (AFP) measurement. RESULTS: Thirty two patients (18 males) were included in the study. Mean age of patients was 45.7 years. Fifteen patients (47%) received mesenchymal stem cell (MSC), 9 (28%) received bone marrow mononuclear cells, 5 (16%) were given CD 133-positive bone marrow cells, and 3 (9%) patients received CD 34-positive bone marrow cells. Mean duration of follow up was 20.5months. Mean serum level of AFP was 2.8 ng/ml at baseline and 3.4ng/ml at the end of follow up (p= 0.3). One patient was found to have hepatocellular carcinoma three months after infusion of bone marrow mononuclear cells. The incidence rate for HCC was 1.8 cases per 100 person-years in this study. CONCLUSION: Autologous bone marrow stem cell infusion does not appear to increase the risk of hepatocellular carcinoma. The incidence rate of HCC in this study is comparable or even less than the reported rates of HCC in cohort studies of cirrhotic patients.
BACKGROUND: During the resent years there has been interest in using bone marrow stem cells to treat liver cirrhosis. However, there is a potential concern for malignant transformation after stem cell therapy. The aim of this study was to evaluate the development of hepatocellular carcinoma (HCC) after autologous bone marrow stem cell transplantation for liver cirrhosis. METHODS: All the patients who underwent autologous stem cell transplantation for liver cirrhosis between 2005 and 2011 at our center were enrolled. Cellular infusion was made through peripheral vein, portal vein, or hepatic artery.The patients were invited to undergo screening for hepatocellular carcinoma. The screening was made with ultrasonography and alpha-feto protein (AFP) measurement. RESULTS: Thirty two patients (18 males) were included in the study. Mean age of patients was 45.7 years. Fifteen patients (47%) received mesenchymal stem cell (MSC), 9 (28%) received bone marrow mononuclear cells, 5 (16%) were given CD 133-positive bone marrow cells, and 3 (9%) patients received CD 34-positive bone marrow cells. Mean duration of follow up was 20.5months. Mean serum level of AFP was 2.8 ng/ml at baseline and 3.4ng/ml at the end of follow up (p= 0.3). One patient was found to have hepatocellular carcinoma three months after infusion of bone marrow mononuclear cells. The incidence rate for HCC was 1.8 cases per 100 person-years in this study. CONCLUSION: Autologous bone marrow stem cell infusion does not appear to increase the risk of hepatocellular carcinoma. The incidence rate of HCC in this study is comparable or even less than the reported rates of HCC in cohort studies of cirrhotic patients.
Authors: M Chiaramonte; T Stroffolini; A Vian; M A Stazi; A Floreani; U Lorenzoni; S Lobello; F Farinati; R Naccarato Journal: Cancer Date: 1999-05-15 Impact factor: 6.860
Authors: Madhava Pai; Dimitris Zacharoulis; Miroslav N Milicevic; Salah Helmy; Long R Jiao; Natasa Levicar; Paul Tait; Michael Scott; Stephen B Marley; Kevin Jestice; Maria Glibetic; Devinder Bansi; Shahid A Khan; Despina Kyriakou; Christos Rountas; Andrew Thillainayagam; Joanna P Nicholls; Steen Jensen; Jane F Apperley; Myrtle Y Gordon; Nagy A Habib Journal: Am J Gastroenterol Date: 2008-07-12 Impact factor: 10.864
Authors: Myrtle Y Gordon; Natasa Levicar; Madhava Pai; Philippe Bachellier; Ioannis Dimarakis; Faisal Al-Allaf; Hanane M'Hamdi; Tamara Thalji; Jonathan P Welsh; Stephen B Marley; John Davies; Francesco Dazzi; Federica Marelli-Berg; Paul Tait; Raymond Playford; Long Jiao; Steen Jensen; Joanna P Nicholls; Ahmet Ayav; Mahrokh Nohandani; Farzin Farzaneh; Joop Gaken; Rikke Dodge; Malcolm Alison; Jane F Apperley; Robert Lechler; Nagy A Habib Journal: Stem Cells Date: 2006-03-23 Impact factor: 6.277
Authors: N Levicar; M Pai; N A Habib; P Tait; L R Jiao; S B Marley; J Davis; F Dazzi; C Smadja; S L Jensen; J P Nicholls; J F Apperley; M Y Gordon Journal: Cell Prolif Date: 2008-02 Impact factor: 6.831
Authors: Mahshid Saleh; Mohammad Taher; Amir Ali Sohrabpour; Amir Abbas Vaezi; Mohsen Nasiri Toosi; Maria Kavianpour; Zeinab Ghazvinian; Shahrokh Abdolahi; Javad Verdi Journal: Cell Biosci Date: 2020-05-24 Impact factor: 7.133